Cheers for that, I must have missed that guidance on the...

Cheers for that, I must have missed that guidance on the website.
I think it may need updating though based on an update provided with the last quarterly:

" Chief among these has been industry-wide factors that have delayed site readiness to initiate screening activities for three months or more after activation. As a result, the milestone for lymphodepletion regimen selection and futility analysis has been shifted by approximately two quarters and is now expected in the first half of 2026.
...
The Company will intentionally hold off on projecting additional milestones until after the first milestone for lymphodepletion regimen selection and futility analysis. Recognizing the strategic significance of this inflection point and guided by stakeholder feedback, the Company is re-evaluating what data will be appropriate to share at the time of the lymphodepletion announcement."

https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-first-quarter-2025-financial

They must have some decent backing from the FDA to provide that sort of guidance though. Most patients who relapse with MRD+ do so in the first 24 months, so assessing PFS of patients within 12-24months from treatment may only indicate a delay in relapse. Guess we'll have to wait and see just how emphatic the interim data is then hope for patients and investors that durability is maintained through the rest of the trial.

I don't really have enough time in my life to deep dive and do the due diligence on everything across all my investments, but every time I do I'm reminded of how uncertain R&D companies really are. I'm always surprised how quickly commentators on HC are willing to write-off (or write-in) clinical assets based off partial or interim Phase 1 data of assets, their competitor's assets, or similar drugs/reformulations. Guess that's just the nature of the beast though.